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Objective: The aim of this study was to review statistical techniques for estimating the mean 
population cost using health care cost data that, because of the inability to achieve complete 
follow-up until death, are right censored. The target audience is health service researchers 
without an advanced statistical background.
Methods: Data were sourced from longitudinal heart failure costs from Ontario, Canada, and 
administrative databases were used for estimating costs. The dataset consisted of 43,888 patients, 
with follow-up periods ranging from 1 to 1538 days (mean 576 days). The study was designed so 
that mean health care costs over 1080 days of follow-up were calculated using naïve estimators 
such as full-sample and uncensored case estimators. Reweighted estimators – specifically, the 
inverse probability weighted estimator – were calculated, as was phase-based costing. Costs 
were adjusted to 2008 Canadian dollars using the Bank of Canada consumer price index (http://
www.bankofcanada.ca/en/cpi.html).
Results: Over the restricted follow-up of 1080 days, 32% of patients were censored. The full-
sample estimator was found to underestimate mean cost ($30,420) compared with the reweighted 
estimators ($36,490). The phase-based costing estimate of $37,237 was similar to that of the 
simple reweighted estimator.
Conclusion: The authors recommend against the use of full-sample or uncensored case estima-
tors when censored data are present. In the presence of heavy censoring, phase-based costing 
is an attractive alternative approach.
Keywords: health care costing, heart failure, incomplete data, statistical techniques, phase-
based costing
Introduction
Accurate estimates of health care costs have a wide range of applications and are of 
growing importance to both policy makers and clinicians, given the burgeoning costs 
of health care delivery, budgetary constraints, and the aging population. Therefore, 
it is important for health services researchers to be familiar with robust methods for 
description, inference, and prediction using costing data.
A number of statistical properties of costing data preclude the use of traditional 
statistical tools.1,2 There is a rich econometric and statistical literature focused pre-
dominantly on three specific properties of cost data: first, a substantial proportion of 
the general population may be healthy, requiring little medical care and having zero 
costs; second, the distribution of health care costs for those who do incur costs is 
usually heavily right skewed, with a few very high-cost individuals on the tail; third, 
investigators have shown that the assumption of homoscedasticity (ie, constant variance 
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in the error term) is often violated and thereby alternative 
modeling techniques are required.2–6
A fourth obstacle is incomplete data when health care 
expenses are not available for all participants for the entire 
period of interest. Although this area is one of active research, 
much of this work has been presented in health economics or 
statistical journals.3,7–13 The objective of the present review is 
to examine this fourth obstacle in detail, targeting an audience 
of health services researchers without an advanced statistical 
background. The authors will focus on the basic operation 
of estimating mean health care costs, using both simulations 
and a case study to illustrate these concepts. In the process, 
the goal is to provide some of the necessary background to 
make this important area of study more accessible.
The case study was of patients with heart failure (HF) in 
Ontario, Canada.14 Briefly, all patients with an admission for 
HF, based on International Classification of Disease Version 
10 Code I50, during the period 2004–2006 were identified 
in the Canadian Institute for Health Information’s Discharge 
Abstract Database. Costs for hospital admission, same-day 
surgeries, physician services, ambulatory care, and HF 
medications were estimated in 30-day intervals until March 
31, 2008.14 Throughout the text, the example of cumulative 
3-year costs, approximated as 1080 days based on the 30-day 
costing interval, will be used. Costs were adjusted to 2008 
Canadian dollars using the Bank of Canada consumer price 
index (http://www.bankofcanada.ca/en/cpi.html). The dataset 
consisted of 43,888 patients, with follow-up periods ranging 
from 1 day to 1538 days (mean 576 days). Mean age was 
76 years (range 25–106 years), with 51% females and 72% 
with an ischemic cardiomyopathy.
Cumulative cost functions
For a longitudinal health care costing study, the costing value 
of greatest interest is the mean health cost (also known as 
incidence-based costs), defined as the cumulative cost from 
the index event over some interval. The incidence-based 
costs must be contrasted with prevalence-based costs, 
where the costs for the entire population are assessed in a 
cross-sectional fashion and are then divided by the number 
of members. Incidence-based cumulative cost functions for 
an individual can be complex, as illustrated in Figure 1A. 
The rate of cost accumulation tends to increase around 
index events such as hospitalizations and death, as shown 
by the dashed line and the varying slope of the solid curve 
in Figure 1A. Moreover, the pattern of cost accumulation 
may be different between any two individuals. One could 
theoretically follow all participants until death; however, 
death will rarely be observed for every participant because 
of short study horizons. Indeed, the portion of health care 
cost that is unobserved in this setting may be especially 
important, because health care costs tend to rise dramatically 
in the period prior to death.2,15–17 To avoid this issue, a study 
may instead focus on the mean total costs for a restricted time 
period (eg, 1080-day total health care costs).18 This creates 
two major issues.
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Figure 1 (A) Cumulative costs and flow of costs in complete case; (B) cumulative costs in censored case.
Notes: S(t) is probability of survival; Sc(t) is probability of being uncensored; t is follow-up time in days; C indicates censored time; L indicates the restricted time limit; 
the solid line shows cumulative costs over time; the dashed/dotted line shows the rate of cost accumulation or flow of costs at a particular time; shaded area represents 
unobserved costs accrued from the time of being censored to either death or the full time period of interest; t is follow-up time in days.
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First, among the participants who die, death drives 
up costs in the period before death as seen in Figure 1A. 
Conversely, cumulative costs may in fact be driven down 
because no costs are accrued after death. The accepted 
method of dealing with this is to consider death as a terminal 
event.7,9,11,12,18 Subjects will accrue costs until they die, or until 
they reach the time horizon of the analysis. A complete case 
is defined as one in which death occurs, or where follow-up 
is complete until the end of the restricted time period. In each 
of these situations, participants are no longer accumulating 
relevant costs.
The second issue is how to deal with the individuals who 
are not complete cases. A portion of the relevant health costs 
for these participants will be unobserved, as illustrated by the 
shaded area in Figure 1B.18 Such data are said to be right cen-
sored, defined as an observation that ends prematurely, before 
the outcome of interest has occurred (death or 1080 days, in 
the present example).18 Right censoring of health care costs 
can arise from a number of mechanisms. Patients may be 
lost to follow-up at varying times; alternatively, a study may 
enroll patients over a period of time but discontinue follow-up 
on a fixed calendar date. In both of these cases, the censoring 
occurs completely at random, and the observed health care 
costs represent the lower limit of the relevant costs. One way 
of adjusting cumulative cost estimates for censoring is to 
develop a function that describes the way in which data are 
censored and to use that function to reweight the observed 
cost data. Kaplan-Meier techniques are a well-established 
method to achieve such reweighting.
Kaplan-Meier estimates  
for survival and censoring
First, the traditional Kaplan-Meier estimator for survival will 
be reviewed, and then an analogous estimator for censoring 
will be introduced.12 Please see Table 1 for explanation of 
the nomenclature in this section. A traditional Kaplan-Meier 
estimator, S(t) is the probability of surviving beyond a time, t. 
In this method, patients who are censored are no longer at 
risk for death and are therefore excluded. The probability of 
survival for any interval is equal to the proportion surviving 
among those still at risk of death at the beginning of the 
interval (ie, uncensored cases). The Kaplan-Meier estima-
tor at time t is calculated by multiplying the probabilities of 
surviving each time interval preceding point t – hence, it is 
also referred to as the product-limit estimator.
The Kaplan-Meier estimate for censoring, Sc(t), is defined 
as the probability for being uncensored beyond time t.12 Here, 
the role of death and censoring are reversed relative to a 
conventional survival analysis. Censoring is the outcome of 
interest, and death simply means that the patient is excluded 
from further observations. The risk of being uncensored in 
a particular interval is calculated for those who are “at risk” 
of being censored at the beginning of the interval. These are 
the patients who have not been removed or excluded – that 
is, those who have not died or been censored. Again, Sc(t) for 
time t is the product of all probabilities of being uncensored 
across intervals prior to time t.
To illustrate these concepts, four hypothetical patients 
are presented in Table 2, followed over 6 months. Patients 
A and B are followed for all 6 months, while patient C 
dies in month 3 and patient D is censored in month 4. The 
components for both the Kaplan-Meier estimates for sur-
vival, S(t), and the Kaplan-Meier estimates for censoring 
conditional on being alive, Sc(t), are shown on the right of 
the Table 2. When calculating the Kaplan-Meier estimate 
for survival, it is necessary to determine the probability of 
death and of survival for each month. These are shown with 
the number of patients at risk at the beginning of the month 
in the denominator. Importantly, patients who are censored 
are removed from the denominator. For example, in the third 
month, four patients are at risk for death at the beginning of 
the month, with three alive at the end of the month (prob-
ability of survival is 3/4 = 0.75). In month 5, only two are at 
risk for death at the beginning of the interval, because one 
patient was censored in the previous month (probability of 
survival is 2/2 = 1). S(t) is the product across the months of 
the probability of survival: S(4) = 1*1*0.75*1 = 0.75.
The corresponding calculations for Sc(t) are shown on 
the far right side of Table 2. Here, the denominator for each 
interval contains only patients at risk for censoring at the 
Table 1 Nomenclature
Term Definition
S(t) Probability of being alive beyond time t
Sc(t) Probability of being uncensored beyond time t
i Individual
N Total number of individuals in study
j Cost interval (ie, 30 days)
K Total number of costing intervals
Ci
total Accumulated cost for individual i
ti Period of observation for individual i
Ti
L Time of observation until death/cure/end of relevant period 
for an individual who is considered a complete observation
Ti
C Time of observation until censoring for an individual who 
is censored
Ai(ti) The cost function used to estimate cumulative cost until 
time t for patient i
Mi
j The total cost for each subinterval j for each patient i
R Rate of cost accumulation
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beginning of the interval; patients who died in the   preceding 
interval are removed. For example, at the beginning of the 
fourth month, only three patients continue to be at risk 
for censoring. In the end of the fourth month, one patient 
was censored, so the probability of being uncensored is 
2/3 = 0.67. The Kaplan-Meier estimate Sc(t) is the product 
across intervals of the probability of remaining uncensored: 
Sc(4) = 1*1*1*0.67 = 0.67.
In Figure 2A, the Kaplan-Meier survival curve is 
constructed from the HF study over a follow-up period of 
1080 days, with the probability of survival, S(t), at the end 
of follow-up being 43%. It is evident that the probability of 
dying – the complement of S(t) – increases with larger values 
of t, after accounting for censoring.
Over the full follow-up period of 1080 days, 14,107 patients 
of the original 43,888 patients were censored and therefore 
were no longer available for observation. In Figure 2B, the 
corresponding Kaplan-Meier curve is constructed, with the 
probability of being uncensored, Sc(t), decreasing at greater 
values of t. It is important to note that at greater values of time 
t, the probability of censoring increases – the   complement 
of Sc(t).
Restricted time period total costs
First, the issues related to censoring in a restricted time period 
will be tackled. In order to understand the techniques, some 
nomenclature is necessary (see Table 1). Let N be the total 
sample size of the study, including both censored and uncen-
sored cases. For each participant, i, there is an observed accu-
mulated medical cost, denoted by Ci
total. Each individual has 
an observation time, denoted by ti. For complete cases who 
are observed until death or until the end of the restricted time 
period, ti is equal to the time to death/restricted time limit, 
denoted by Ti
L. For a censored case, ti is equal to the time to 
censoring, denoted by Ti
C. Finally, an indicator variable is 
defined for each participant, ∆i, which will take the value of 
0 for censored cases and of 1 for complete cases. Ci
total for 
each participant will be expressed as a function Ai:
 C i
total = Ai(ti)  (1)
Each of these terms is illustrated in Figure 1A and B. 
Figure 1A shows the cumulative costs over time for a com-
plete case, defined as a participant who is observed until 
Ti
L. Figure 1B is a censored patient, observed only until 
the censoring time, Ti
C. As illustrated by the shaded area, a 
censored patient will continue to accumulate relevant costs 
(ie, until Ti
L) and these will be unobserved.
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Full-sample and uncensored  
case estimators
Two potential estimators for mean restricted time total costs 
(Ci
total) in the face of censored data are the full-sample and 
uncensored case estimators.1,9,13 In the full-sample estima-
tor, the accumulated cost for each participant is averaged, 
irrespective of whether the patient died, was observed for 
the full follow-up period, or was censored.1,13 As censored 
patients will continue to accumulate relevant costs while 
unobserved (shaded portion in Figure 1B), the full-sample 
estimator would include only a portion of their relevant costs, 
and therefore it will always be an underestimate.1
In the uncensored case estimator, only the values from 
complete cases are used.13 As illustrated in Figure 2B, the 
probability of remaining uncensored, Sc(t), is not uniform 
at all values of t. Instead, as t increases, the probability of 
being uncensored, Sc(t), decreases. Therefore, the uncen-
sored case estimator would be biased toward the costs 
of participants who died early – those who had smaller 
values of ti.1,13
Reweighted estimators
One approach to estimate mean health care costs when 
censoring is present is to reweight each complete case so 
that each complete case represents not only itself but also 
some number of incomplete/censored cases. In this setting, 
the cumulative cost of each participant who died or reached 
the full period of observation must represent not only the 
cost of that participant but also the censored cases that 
would have been observed had there been no censoring. 
The number of censored cases that must be represented by 
a complete case at observation time t is proportional to the 
probability of that case being censored.18,19 It follows that 
costs for complete cases with a short follow-up should be 
weighted less than cases with a longer observation period, 
accounting for the higher probability of censoring with 
longer observation periods.
Different  reweighted  estimators  have  been 
developed.1,9,13,18,20,21 These are conceptually similar and are 
equivalent under certain conditions.12,21 The Lin 1997 esti-
mator was the first to be described and is based on dividing 
observation time into a number of equal intervals.9 Lin et al9 
described two alternative methods: one if cost histories are 
available, and a second if only total cumulative costs are 
available for all individuals. In the latter, more basic scenario, 
the mean cost for each interval is calculated, based only on 
the costs of patients who die during the interval. The cumula-
tive cost for the entire period of observation is the sum of the 
mean costs for each interval, weighted by the Kaplan-Meier 
probability of surviving to the beginning of each interval.9 
A limitation of the Lin 1997 estimator is the assumption of 
discrete censoring times that coincide with the beginning of 
the costing intervals.22 Bang and Tsiatis7 described an inverse 
probability weighted (IPW) estimator that did not require 
interval costs and which accommodated continuous censoring 
times. As an illustration, the IPW method of Bang and Tsiatis7 
will be worked through in detail here. Interested readers are 
encouraged to refer to the source documentation for a full 
description of the other estimators, and for recommendations 
as to their appropriate use.1,9,12,13,18,20,21
In the IPW estimator, sample weighting is done 
using the Kaplan-Meier estimate for censoring, Sc(ti).1,21 
Each uncensored participant (∆i value of 1) with Ti
L 
1
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Figure 2 (A) Kaplan-Meier survival curve (B) Kaplan-Meier curve for censoring
Notes: S(t) is probability of survival; Sc(t) is probability of being uncensored; t is follow-up time in days.
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of observation time has Sc(Ti
L) probability of being 
  uncensored, as seen in Figure 2B. Each uncensored 
  observation   represents on average 1/Sc(Ti
L) patients who are 
censored (∆i value of 0).12 Because uncensored   observations 
are weighted by the inverse of Sc(ti), it is apparent that 
patients who die early in the study (smaller values of ti), 
and who therefore have smaller values of Ti
L, are weighted 
less than those who die at longer follow-up times or who 
are followed up until the restricted time limit. The mean 
IPW total cost is estimated as:
  1/N[∑i
n∆iAi(ti)/Sc(ti)]  (2)
Several key points from this merit discussion. Costs from 
all individuals are included, as N is the full sample. However, 
the costs of the censored participants are multiplied by the 
indicator variable of “0,” with only the costs of complete 
participants reweighted accordingly. An important limita-
tion for this estimator is inefficiency, because only data from 
uncensored/complete cases inform the final value.13 Using 
simulation, Raikou and McGuire13 found that in the presence 
of very heavy censoring (.50%), the simple IPW estimator 
becomes unstable.
An alternative “partitioned estimator” is possible when 
cumulative cost histories are available for each participant. 
This is shown in Figure 3, where costs are available for sub-
intervals of the full period of observation.12 Censored patients 
are likely to have full costs for some of the   subintervals. For 
example, in Figure 3, patient 2 is a complete case over the 
entire restricted time period (shaded area), and therefore 
patient 2 has complete costs for all four subintervals; patient 
1 is censored in subinterval 3 but has full costs for subinterval 
1 and 2 (shaded area). Because a censored patient is likely 
to have complete costs for some intervals, it is possible to 
make use of these data to further inform the estimator of 
mean cost.
Bang and colleagues7,21 developed a partitioned exten-
sion of their IPW estimator, in which the total time period 
is divided into K partitions or subintervals. For each subin-
terval, denoted as j, a participant will either be censored or 
have full observation, defined as dying within the subinterval 
or observation for the full subinterval. Thus, one can define 
variables ∆i
j, Ti
C, Ti
L, ti
j specific to each subinterval j of inter-
est. Mi
j designates the total cost for each subinterval j. Mi
j is 
calculated as the difference between cumulative cost up to 
the end of the subinterval j and the cumulative cost in the 
preceding subinterval. This is given by the formula:
  Mi
j = [Ai
j(ti
j) − Ai
(j−1)(ti
(j−1))]  (3)
For illustration, in Figure 3, the cost for patient 
1  for  subinterval  2  is  the  difference  between  the 
entire shaded area – the first term in equation 4: Ai
j(ti
j) – and 
the shaded area to the left of the line separating the first and 
second interval – the second term in equation 4: Ai
(j−1)(ti(j−1)). 
By summing the cost estimate for each subinterval, the mean 
12 3
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Figure 3 Partitioned cost histories: the full period of observation is subdivided into four partitions. Patient 1 is censored in partition 3, while patient 2 is a complete case.
Notes: Shaded area represents partitions for patients 1 and 2, where full data is available; t is follow-up time.
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total cost can be determined. The mean partitioned IPW 
estimator for total restricted time costs will then be:
  1/N[∑i
n∑j
K ∆i
jMi
j/Sc(ti)]  (6)
Investigators have shown that the Lin 1997 method 
and the IPW estimator are equivalent when the intervals 
for the Lin 1997 method become infinitesimally small (ie, 
approach continuous censoring time).12 In order to extend 
beyond estimation of the mean and make formal inferences, 
both the Lin 1997 and Bang-Tsiatis methods allow for the 
calculation of variances. These calculations are   necessarily 
complex –   readers are encouraged to review the source 
documentation on this area and are strongly encouraged to 
involve a   statistician. Moreover, using the simple IPW or 
the partitioned IPW as response variables, these methods 
can be expanded within a regression framework to control 
for covariates.10,11,18 However, the IPW techniques have a 
number of limitations, especially when evaluating covari-
ate effects, as the effects on cost accumulation cannot be 
distinguished from the effects on survival.22 Moreover, 
these techniques do not account for the differential rates 
of heath care cost accumulation near death, as seen in 
Figure 1A and B. Alternative models have been developed 
to deal with these issues.22
Simulations
The authors used a similar simulation method to Basu and 
Manning22 to generate a cohort of 1000 patients, evaluated 
over a maximum of ten equally spaced intervals. Patients 
who died or who completed observation until the end of the 
ten periods were considered to be complete observations. 
Survival and censoring times were generated from an expo-
nential distribution and a uniform distribution, respectively.22 
As per previous investigators, the present authors generated 
a cumulative cost profile for individuals, such that there was 
an increased initial cost reflecting diagnosis and an increased 
terminal cost in the event of death.
The authors used combinations of censoring and survival 
times to create datasets with increasing degrees of censoring. 
Using 500 simulations per dataset, the authors then compared 
a full-sample, uncensored, and simple IPW estimator with the 
true mean costs. These results are shown in Table 3.
As expected, with increasing censoring, the full-sample 
estimator underestimated the true costs. The simple IPW 
estimator performed well with mild to moderate degrees of 
censoring in the simulated datasets; however, with heavy 
censoring (53%) it substantially overestimated true costs. 
This is consistent with reports with other investigators as to 
its instability in the presence of high censoring.
HF case study
Using data from the 43,888 patients in the HF case study, 
the authors calculated estimators for the mean 1080-day total 
cost. Cost histories were available for 180-day partitions. 
Statistical models were created using R software (v 2.9.0; R 
Foundation for Statistical Computing, Vienna, Austria) and 
are available upon request. Of the 43,888 patients, 32.1% 
were censored over the 1080-day restricted time period, with 
50.9% of patients dying and 17% having complete follow-up 
to 1080 days. In Table 4, the full-sample estimator, uncen-
sored case estimator, simple IPW estimator, and the parti-
tioned 180-day estimator are shown. In addition, the authors 
estimated costs using the Lin 1997 method based on total 
accumulated costs. Two versions of the Lin 1997 method, 
using 180- and 30-day intervals, were utilized to highlight 
issues that may arise from the choice of time-interval.
As anticipated, the full-sample estimator was the lowest, 
at $30,420 for the 3-year (1080-day) period, which is a biased 
underestimate. A total of 14,107 patients were censored 
within the restricted time period and had costs that would 
Table 3 Simulations to evaluate impact of censoring
Censoring Mean ten-interval  
cumulative costs ($)a
Interquartile   
range
7% Censoring
True costs 8.29 8.21–8.38
Full-sample estimator 7.49 7.41–7.56
Uncensored case  
estimator
7.68 7.61–7.77
Simple IPW 8.06 7.97–8.15
18% Censoring
True costs 8.29 8.20–8.37
Full-sample estimator 7.03 6.96–7.10
Uncensored case  
estimator
7.50 7.42–7.58
Simple IPW 8.49 8.39–8.59
21% Censoring
True costs 9.07 9.00–9.16
Full-sample estimator 7.57 7.49–7.65
Uncensored case  
estimator
8.20 8.12–8.28
Simple IPW 9.35 9.24–9.45
53% Censoring
True costs 7.45 7.37–7.53
Full-sample estimator 4.90 4.89–5.04
Uncensored case  
estimator
5.28 5.18–5.38
Simple IPW 9.87 9.64–10.1
Note: aCosts adjusted to 2008 Canadian dollars using the Bank of Canada consumer 
price index (http://www.bankofcanada.ca/en/cpi.html).
Abbreviation: IPW, inverse probability weighting.
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have otherwise accrued in the absence of censoring (ie, the 
shaded portion in Figure 2B). The uncensored estimate is 
higher, at $33,940, and disproportionately biased patients 
with short survival times, who in this dataset have higher 
costs. The simple IPW cost of $36,490 only makes use of the 
67.2% of data not censored. With the partitioned IPW estima-
tor, which makes use of data from all the subjects, the estimate 
for mean 1080-day cumulative cost was $33,230. In contrast, 
the Lin 1997 method, based on intervals of 180 days, provides 
a substantially lower mean estimate of $20,059, while the 
Lin 1997 estimate using a 30-day interval of $37,042 closely 
approximated the simple IPW estimate. This highlights the 
differences between the Lin 1997 methods and the IPW 
estimator when longer time intervals are used.
Lifetime costs
Although using a restricted time period allows one to circum-
vent the issue of extrapolating lifetime costs and is often used 
in practice, a restricted time period cost has important limita-
tions.18 For example, two patients may have the same lifetime 
cumulative costs but because of differences in survival times 
(ie, one patient dies at 3 years and the other dies at 5 years), 
may have substantially different time-restricted costs at 
3 years.18 When studying interventions with significant influ-
ences on mortality, having the same distribution of lifetime 
costs in the control and study groups is not synonymous with 
having the same distribution of time-restricted costs, because 
the survival distributions in the groups may be different.
Given the critical relationship between survival time and 
health care costs, it is tempting to use Kaplan-Meier techniques, 
substituting time to death with cost to death as the dependent 
variable. However, investigators have found that this results 
in biased estimates.3,8,18,23 A fundamental requirement for a 
Kaplan-Meier survival curve is independent censoring.3,8,18,23 
For survival time, this requires that the time to censoring is 
independent of the time to death. In most cases this is true; 
however, in the parallel form for costs, the cumulative cost to 
censoring for a particular participant will not be independent 
from the cumulative costs to death because both are related 
to the participant’s unique pattern of cost accumulation 
(Figure 1A).3,8,18,23 This is most obvious in the situation of a 
constant rate of cost accumulation, R, where the cumulative 
cost at censoring time, Ti
C, is simply the product of R*Ti
C, while 
that at time of death, Ti
L, is R*Ti
L. Both values are clearly not 
independent but are related to each other by R.3,8,18,23
Phase-based costing
An alternative method for estimating cumulative costs is 
using is a phase-based modeling approach.14,24–26 This is par-
ticularly attractive for estimating lifetime costs or cost in the 
presence of heavy censoring. The steps for the phase-based 
approach are as follows:14,24–26
1.  Define a priori clinically important phases of disease. 
Examples are the phase immediately after diagnosis, 
associated with higher costs; a stable phase, with constant 
and low costs; and the phase prior to death, which again 
has high costs.
2.  Determine inflection points in cumulative cost, which 
define the duration of each phase. This will be disease 
specific.
3.  Allocate observation time and costs for each patient to 
the phases.
4.  Once the costs for all patients have been assigned, deter-
mine the mean cost per phase (or per subdivision of each 
phase).
5.  Using both the data on cost per phase and time to death, 
determine the cumulative lifetime costs.
Each of these steps will now be worked through in the 
HF example. First, based on content experts, the authors 
expected that HF would be characterized by at least three 
phases: (1) a post-discharge phase after index   hospitalization, 
(2) a pre-death phase, and (3) a relatively stable phase (Step 1). 
To confirm this hypothesis, the authors evaluated the cost per 
30 days for patient subgroups that survived 9–12, 21–24, and 
33–36 months post discharge (Appendix Figure 1). The mean 
30-day cost curves confirmed the hypothesis of discrete cost 
phases with inflection points separating the post-discharge 
and stable phases, and the stable and pre-death phases esti-
mated at 3 months post discharge and 6 months prior to death, 
respectively (Step 2).
The cumulative cost history for each individual over the 
1080-day period of the study was partitioned and sequentially 
allocated to phases (Step 3). For example, for each patient the 
Table 4 Mean 1080-day costs using different estimating methods
Estimating method Mean 1080-day  
cumulative costs ($)a
Interquartile   
range
Full-sample estimator 30,420 10,060–37,850
Uncensored case  
estimator
33,940 11,480–42,890
Simple IPW 36,490 0–44,620
Partitioned IPW 33,230 10,260–40,550
Lin 1997 (180-day interval) 20,059 NAb
Lin 1997 (30-day interval) 37,042 NAb
Notes:  aCosts  adjusted  to  2008  Canadian  dollars  using  the  Bank  of  Canada 
consumer  price  index  (http://www.bankofcanada.ca/en/cpi.html);  bthe  Lin  1997 
method produces a single mean value for the sample, as opposed to a reweighted 
estimate for each individual – as such, an interquartile range is not available.
Abbreviations: NA, not applicable; IPW, inverse probability weighting.
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cumulative costs for the first 3 months of observation were 
assigned to the post-diagnosis phase, the costs associated 
with the 6 months prior to death were assigned to the pre-
death phase, and the remainder were assigned to the stable 
phase. Once the entire cohort was analyzed in this manner, a 
mean cost was calculated for each of the phases (Step 4). In 
the present study, the mean costs were determined for each 
30-day block within each phase (Appendix Table 1). Other 
investigators have used a simpler approach in which a single 
mean cost is determined per phase.27 It is important to note 
that costs should be adjusted to the current year in order to 
account for health care inflation, using a multiplier such as 
the consumer price index.
To calculate cumulative costs, one utilizes both the mean 
costs per phase and a survival function that spans the time 
horizon of the study (lifetime or shorter) (Step 5). Although 
the survival and cost data are from the same cohort in the 
earlier techniques, this need not be the case in the phase-based 
approach.28 In the present study, the authors used a survival 
curve from a separate HF cohort that had been followed for 
12 years, over which period 99% of patients died.
First, the survival curve is divided into intervals. In the 
present example the authors used 30-day time intervals. 
For any time interval on the survival curve, the proportion 
of the original cohort in each phase is determined. This 
proportion is multiplied by the mean cost for that particular 
phase. In Figure 4, for example, at the 120- to 150-day time 
interval on the survival curve, 68.4% of the original HF 
cohort were in the stable phase – the cost for this phase was 
0.684*$617 = $422. None of the patients were in the post-
discharge phase, and 10.5% were in the pre-death phase (for 
a cost of $614). Thus, the cost for t = 120- to 150-day interval 
is $422 + $614 = $1036. The costs for all time intervals are 
calculated in this manner and are summed to produce the 
mean cost for the entire time horizon.
The authors found that over a mean life expectancy of 
3.87 years, HF patients had a mean lifetime cost of $61,870.14 
To provide a comparison with the methods already   mentioned, 
1
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Figure 4 Merging phase-based costs on the survival curve. For the time interval 120–150 days, 68.4% of the original cohort was in the stable phase, with 10.5% in the 
pre-death phase. To determine the cost for the time interval of 120–150 days, the proportion of patients in each phase is multiplied by the mean cost per phase, as 
shown in Appendix Table A1.
Notes: S(t) is probability of survival; t is follow-up time in days.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
153
Censored health care costsClinicoEconomics and Outcomes Research 2012:4
the authors also calculated the mean cost at 1080 days, using a 
phase-based approach. The phase-based estimate of $37,237 
was similar to that from the other methods – specifically, the 
simple IPW and the Lin 1997 methods.
Data comparing such phase-based estimates with those 
from IPW methods are sparse, but with investigators to 
date finding that they are comparable.26 The benefits of the 
phase-based approach are that actual costs for the cohort 
over the entire period of interest (ie, lifetime) do not need 
to be observed, thereby overcoming the major limitation of 
the previous methods.14,24–26 Using these methods, investiga-
tors have been able to produce widely used estimates of the 
lifetime costs of cancer.26,29 However, greater understanding 
of when one technique is favored over another is important 
and should be a focus for further methodological study.
Conclusion and recommendations
This review has provided an overview for the uninitiated reader 
who wishes to tackle the literature on health care costing with 
data that are incomplete because of incomplete follow-up. The 
authors offer the following recommendations:
1.  Censoring will have substantial methodological impact 
on a study, and investigators must evaluate their data to 
determine if any cases are right censored.
2.  If censoring is present, the use of either a full-sample 
estimator or an uncensored case estimator in the estima-
tion of mean cost is potentially inaccurate.
3.  The choice of estimator when censoring is present is not 
clear-cut. Options include a weighted estimator (prefer-
ably a partitioned estimator, to make use of all the data 
efficiently) or a phase-based approach.
Given the importance of health care costing for compara-
tive effectiveness research and in the shaping of future health 
policy, the authors believe that further work on developing 
accurate yet transparent techniques should be a priority; the 
authors’ hope is that this review serves as a stimulus for 
such work.
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Figure A1 Exploratory analysis on phases of long-term costa associated with heart failure care.
Note: aCosts adjusted to 2008 Canadian dollars using the Bank of Canada consumer price index (http://www.bankofcanada.ca/en/cpi.html).
Table A1 Phase-based costing example using heart failure cohort
30-day block Observed costs ($)a
Post-discharge phase
Block 1 10,675
Block 2 2961
Block 3 2172
Stable phase
All blocks 617
Pre-death phase
Block 6 3062
Block 5 3501
Block 4 4077
Block 3 5119
Block 2 8716
Block 1 8308
Mean lifetime cost 61,870
Note: aCosts adjusted to 2008 Canadian dollars using the Bank of Canada consumer 
price index (http://www.bankofcanada.ca/en/cpi.html).
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